title: Low-Grade Serous Carcinoma of the Ovary.
authors.forename: Rachel N
authors.initials: RN
authors.lastname: Grisham
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D018284:Cystadenocarcinoma, Serous / Q000097:blood / Q000175:diagnosis / Q000235:genetics / Q000401:mortality / Q000628:therapy; D005260:Female; D006801:Humans; D008565:Membrane Proteins / Q000097:blood; D009154:Mutation; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis / Q000235:genetics / Q000401:mortality / Q000628:therapy; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis / Q000235:genetics / Q000401:mortality / Q000628:therapy; D010052:Ovariectomy; D048493:Proto-Oncogene Proteins B-raf / Q000097:blood; D016283:Proto-Oncogene Proteins p21(ras) / Q000097:blood; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C117307:KRAS protein, human; C451759:MUC16 protein, human; D008565:Membrane Proteins; D000068258:Bevacizumab; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D016283:Proto-Oncogene Proteins p21(ras)